title: A fragment of human kininogen containing bradykinin blunts the diuretic effect of atrial natriuretic peptide.
abstract: A synthetic 15 aminoacids kinin, named PU-15, is able to block the diuretic natriuretic action of Atrial Natriuretic Peptide (ANP). The structure of PU-15 is Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Iso, having the aminoacid sequence of a fragment of human kininogens. The increase in the urinary excretion of sodium, potassium, and water, elicited by a bolus of 0.5 microg of ANP in anesthetized rats, is blocked by PU-15 (100-150 ng) given either intravenously 3 min before ANP injection, or injected intraperitoneally or in the duodenal lumen, 40 min before ANP. This ANP blockade, which mimics the action of pepsanurin, is only obtained with doses of PU-15 in a narrow range around 100 picomol/rat, and do not modify blood pressure. Larger doses, 2- to 8-fold the effective dose, either do not change the response to ANP or raise the excretion of sodium and water. The administration of HOE-140, a bradykinin B2 receptor blocker, prior to PU-15, completely abolishes the anti-ANP action of PU-15. These findings lend support to the proposal that kinins released from the intestinal tract during prandial period can modulate renal excretory function.
authors.affiliation: Department of Physiological Sciences, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: H R
authors.initials: HR
authors.lastname: Croxatto
authors.forename: X
authors.initials: X
authors.lastname: Figueroa
authors.forename: J
authors.initials: J
authors.lastname: Roblero
authors.forename: R
authors.initials: R
authors.lastname: Albertini
authors.forename: R
authors.initials: R
authors.lastname: Silva
authors.forename: M P
authors.initials: MP
authors.lastname: Boric
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D004232:Diuretics / Q000008:administration & dosage / Q000494:pharmacology*; D004386:Duodenum; D004435:Eating / Q000502:physiology; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007413:Intestinal Mucosa / Q000201:enzymology; D007704:Kininogens / Q000378:metabolism; D008969:Molecular Sequence Data; D009318:Natriuresis / Q000187:drug effects; D010434:Pepsin A / Q000378:metabolism; D010446:Peptide Fragments; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D011188:Potassium / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D043782:Receptor, Bradykinin B2
chemical_list: D065168:Bradykinin Receptor Antagonists; D004232:Diuretics; D007704:Kininogens; C099687:PU-15 protein, synthetic; D010446:Peptide Fragments; D010455:Peptides; D043782:Receptor, Bradykinin B2; C065679:icatibant; D009320:Atrial Natriuretic Factor; C062524:atrial natriuretic factor prohormone (103-125); D010434:Pepsin A; D011188:Potassium; D001920:Bradykinin